Compare QXO & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QXO | FMS |
|---|---|---|
| Founded | 1988 | 1996 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | EDP Services | Misc Health and Biotechnology Services |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6B | 13.9B |
| IPO Year | N/A | 1996 |
| Metric | QXO | FMS |
|---|---|---|
| Price | $25.89 | $24.45 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 13 | 2 |
| Target Price | ★ $33.17 | $30.00 |
| AVG Volume (30 Days) | ★ 9.1M | 806.4K |
| Earning Date | 03-03-2026 | 02-24-2026 |
| Dividend Yield | N/A | ★ 2.37% |
| EPS Growth | N/A | ★ 8.62 |
| EPS | N/A | ★ 2.86 |
| Revenue | $4,662,873,000.00 | ★ $23,046,819,198.00 |
| Revenue This Year | $12,060.43 | $2.13 |
| Revenue Next Year | $61.19 | $2.95 |
| P/E Ratio | ★ N/A | $15.61 |
| Revenue Growth | ★ 8107.98 | 2.10 |
| 52 Week Low | $11.85 | $20.95 |
| 52 Week High | $27.14 | $30.46 |
| Indicator | QXO | FMS |
|---|---|---|
| Relative Strength Index (RSI) | 60.86 | 63.31 |
| Support Level | $20.86 | $23.74 |
| Resistance Level | $23.56 | $24.15 |
| Average True Range (ATR) | 1.17 | 0.38 |
| MACD | 0.24 | 0.23 |
| Stochastic Oscillator | 74.96 | 95.33 |
QXO Inc is the publicly traded distributor of roofing, waterproofing and complementary building products in the United States. The company aims to become the tech-enabled leader in the approximately $800 billion building products distribution industry and generate outsized value for shareholders. It is targeting nearly $50 billion in annual revenues within the next decade through accretive acquisitions and organic growth.
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.